Evidence map›Paper›PMID 36213355›Full record

ArticleJACC. CardioOncology2022

Delphi Panel Consensus Recommendations for Screening and Managing Childhood Cancer Survivors at Risk for Cardiomyopathy.

Rahela Aziz-Bose, Renee Margossian, Bethany L Ames, Kerry Moss, Matthew J Ehrhardt, Saro H Armenian, Torunn I Yock, Larissa Nekhlyudov, David Williams, Melissa Hudson and 2 more

Open access · goldAbstract read
In one paragraph

Article in JACC. CardioOncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Cardio-oncology for Pediatric and Adolescent/Young Adult Patients.Current treatment options in oncology · 2023
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Rahela Aziz-BoseDana-Farber Cancer Institute, Boston, Massachusetts, USA.
Renee MargossianHarvard Medical School, Boston, Massachusetts, USA.
Bethany L AmesGeisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Kerry MossConnecticut Children's Hospital, Hartford, Connecticut, USA.
Matthew J EhrhardtDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Saro H ArmenianDepartment of Pediatrics and Population Sciences, City of Hope, Duarte, California, USA.
Torunn I YockDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Larissa NekhlyudovDana-Farber Cancer Institute, Boston, Massachusetts, USA.
David WilliamsDana-Farber Cancer Institute, Boston, Massachusetts, USA.
Melissa HudsonDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Anju NohriaDana-Farber Cancer Institute, Boston, Massachusetts, USA.
Lisa B KenneyDana-Farber Cancer Institute, Boston, Massachusetts, USA.
Harvard University · USBrigham and Women's Hospital · USSt. Jude Children's Research Hospital · USBoston Children's Hospital · USCity of Hope · USConnecticut Children's Medical Center · USDartmouth–Hitchcock Medical Center · USMassachusetts General Hospital · US

Funding

Research Training in Pediatric OncologyT32CA136432 · NCI · DANA-FARBER CANCER INST · PI SCOTT A ARMSTRONG · 2009 to 2026
$7.9M
NCI NIH HHS T32 CA136432
6 · The paper itself

Abstract

Background: Cardiomyopathy is a leading cause of late morbidity and mortality in childhood cancer survivors (CCS). Evidence-based guidelines recommend risk-stratified screening for cardiomyopathy, but the management approach for abnormalities detected when screening asymptomatic young adult CCS is poorly defined. Objectives: The aims of this study were to build upon existing guidelines by describing the expert consensus-based cardiomyopathy screening practices, management approach, and clinical rationale for the management of young adult CCS with screening-detected abnormalities and to identify areas of controversy in practice. Methods: A multispecialty Delphi panel of 40 physicians with expertise in cancer survivorship completed 3 iterative rounds of semi-open-ended questionnaires regarding their approaches to the management of asymptomatic young adult CCS at risk for cardiomyopathy (screening practices, referrals, cardiac testing, laboratory studies, medications). Consensus was defined as ≥90% panelist agreement with recommendation. Results: The response rate was 100% for all 3 rounds. Panelists reached consensus on the timing and frequency of echocardiographic screening for anthracycline-associated cardiomyopathy, monitoring during pregnancy, laboratory testing for modifiable cardiac risk factors, and referral to cardiology for ejection fraction ≤50% or preserved ejection fraction with diastolic dysfunction. Controversial areas (<75% agreement) included chest radiation dose threshold to merit screening, indications for advanced cardiac imaging and cardiac serum biomarkers for follow-up of abnormal echocardiographic findings, and medical management of asymptomatic left ventricular systolic dysfunction. Conclusions: Expert practice is largely consistent with existing risk-based screening guidelines. Some recommendations for managing abnormalities detected on screening echocardiography remain controversial. The rationale offered by experts for divergent approaches may help guide clinical decisions in the absence of guidelines specific to young adult CCS.

Indexed as

ACE, angiotensin-converting enzymeALVD, asymptomatic left ventricular dysfunctionAYA, adolescent and young adultBNP, brain natriuretic peptidecardiomyopathyCCS, childhood cancer survivor(s)childhood cancer survivorcMRI, cardiac magnetic resonance imagingCOG, Children’s Oncology GroupDelphi methodEF, ejection fractionGLS, global longitudinal strainguidelinesscreeningSF, shortening fraction

Identifiers

PMID36213355
PMCPMC9537072
OpenAlexW4292018384

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.